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Available online 5 June 2019Background: Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1will likely be a critical
component for any effective cure strategy.
Methods: BCN01 trial was a phase I, open-label, non-randomized,multicenter study in HIV-1-positive individuals
diagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed in
the time (8 versus 24 week) between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations. The
primary outcomewas safety. Secondary endpoints included frequencies of vaccine-induced IFN-γ+CD8+ T cells,
in vitro virus-inhibitory capacity, plasma HIV-1 RNA and total CD4+ T-cells associated HIV-1 DNA.
(NCT01712425).
Findings:No differences in safety, peakmagnitude or durability of vaccine-induced responses were observed be-
tween long and short interval vaccination arms. Grade 1/2 local and systemic post-vaccination events occurred in
22/24 individuals and resolved within 3 days. Weak responses to conserved HIV-1 regions were detected in 50%
of the individuals before cART initiation, representingmedian of less than 10% of their total HIV-1-specific T cells.
All participants significantly elevated these subdominant T-cell responses, which after MVA.HIVconsv peaked at
median (range) of 938 (73-6,805) IFN-γ SFU/106 PBMC, representing on average 58% of their total anti-HIV-1 T
cells. The decay in the size of the HIV-1 reservoirwas consistent with the first year of early cART initiation in both
arms.
Interpretation: Heterologous prime-boost vaccination with ChAdV63-MVA/HIVconsv was well-tolerated and
refocusedpre-cART T-cell responses towardsmore protective epitopes, inwhich immune escape is frequently as-
sociated with reduced HIV-1 replicative fitness and which are common to most global HIV-1 variants.
Funding: HIVACAT Catalan research program for an HIV vaccine and Fundació Gloria Soler. Vaccine manufacture
was jointly funded by the Medical Research Council (MRC) UK and the UK Department for International Devel-
opment (DFID) under the MRC/DFID Concordat agreements (G0701669.
Research in Context: Evidence Before this Study: T cells play an important role in the control of HIV infection and
may be particularly useful for HIV-1 cure by killing cells with reactivated HIV-1. Evidence is emerging that not all
T-cell responses are protective andmainly only those targeting conserved regions of HIV-1 proteins are effective,
but typically immunologically subdominant, while those recognizing hypervariable, easy-to-escape
immunodominant ‘decoys’ do not control viremia and do not protect from a loss of CD4 T cells. We pioneereditute, Hospital Universitari Germans Trias i Pujol, Crta Canyet s/n, 08916, Badalona, Barcelona, Spain.
en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
66 B. Mothe et al. / EClinicalMedicine 11 (2019) 65–80a vaccine strategy focusing T-cell responses on the most conserved regions of the HIV-1 proteome using an im-
munogen designatedHIVconsv. T cells elicited by theHIVconsv vaccines inHIV-uninfectedUK and Kenyan adults
inhibited in vitro replication of HIV-1 isolates from 4 major global clades A, B, C and D.
Added Value of this Study: The present study demonstrated the concept that epitopes subdominant in natural
infection, when taken out of the context of the whole HIV-1 proteome and presented to the immune system
by a potent simian adenovirus prime-poxvirus MVA boost regimen, can induce strong responses in patients on
antiretroviral treatment and efficiently refocus HIV-1-specific T-cells to the protective epitopes delivered by
the vaccine.
Implications of all the Available Evidence: Nearly all HIV-1 vaccine strategies currently emphasize induction of
broadly neutralizing Abs. The HIVconsv vaccine is one of a very few approaches focussing exclusively on elicita-
tion of T cells and, therefore, can complement antibody induction for better prevention and cure. Given the cross-
clade reach on the HIVconsv immunogen design, if efficient, the HIVconsv vaccines could be deployed globally.
Effective vaccineswill likely be a necessary component in combinationwith other available preventivemeasures
for halting the HIV-1/AIDS epidemic© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction low-level viral reservoir: the “Mississippi baby” [40,41], and individualsCytotoxic T lymphocytes (CTL) play a key role in the control of
chronic HIV-1 and simian immunodeficiency virus infections [1–3].
HIV-1-specific CD8+ T cells in acute infection appear to be uniquely
able to efficiently suppress viral replication and force escape mutations
[4], whereas CD8+ T-cell responses generated in the chronic infection
often lack this capacity [5]. Multiple strategies to achieve optimal im-
mune control of HIV-1 infection in the absence of cART have been eval-
uated, including a wide range of therapeutic T-cell vaccines [6–11]. The
largest, although still suboptimal, clinical effect demonstrated to date by
active vaccination was obtained by transfer of antigen-pulsed autolo-
gous dendritic cells, which resulted in a 10-fold, but only transient re-
duction in the viral set-point after treatment discontinuation [12].
The failures of past therapeutic vaccines to control HIV-1 replication
in the absence of cART might have been caused by suboptimal specific-
ity and limited breadth of vaccine-induced T-cell responses, due to ei-
ther inadequate immunogen design, its delivery strategy or both [13].
In particular, inclusion of full-length HIV-1 proteins in vaccine immuno-
gens may drive CTL responses towards immunodominant, but often
variable and therefore non-protective ‘decoy’ epitopes similar to those
elicited by natural HIV-1 infection [14]. Thus, some groups have refined
immunogen design by selecting protein segments able to focus T-cell
immunodominance towards more beneficial and conserved determi-
nants [15–17] in order to tackle HIV-1 viral diversity and escape
[18–22] and circumvent the effect of host-genetics in natural response
to HIV-1 [23] (reviewed in [1]).
The HIVconsv T-cell immunogen was constructed by assembling 14
regions that are highly conserved among the fourmajor HIV-1 clades A,
B, C and D into one chimeric protein based on alternating clade consen-
sus sequences [19]. The HIVconsv immunogen delivered by combined
plasmid DNA, non-replicating simian adenovirus and non-replicating
poxvirus MVA regimens was tested in European and African trials in
HIV-1-negative adult volunteers, and demonstrated a good safety pro-
file and induction of high frequencies of CD8+ T cells capable of strong
in vitro HIV-1 inhibition [22,24,25], especially when compared to
those reported in the STEP [26] and RV144 [27] studies. For the
HIVconsv delivery, modified simian (chimpanzee) adenovirus serotype
63 (ChAdV-63) was chosen for its low pre-existing seroprevalence in
human subjects [28], thus avoiding limitations associated with some
of the human adenovirus vectored vaccines [29,30]. MVA was chosen
as the subsequent boost vaccination, since poxviruses were shown to
strongly boost existing CD8+ T-cell responses [31].
Several studies demonstrated that early cART in acute/recent HIV-1
infection improved immune recovery [32,33], reduced the incidence of
AIDS and non-AIDS-related diseases [34], restricted immune escape
[35] and limited the size of latent reservoir [36–39]. However, recent
clinical examples suggested that in the absence of a targeted immune
therapy, HIV-1 could rebound even from an undetectable and/or verytreated in Fiebig I from the SEARCH 010/RV254 Acute HIV Infection co-
hort [42]. Thus, future HIV-1 cure approaches are likely to require a po-
tent T-cell vaccine component [43] that is able to stimulate CTL
responses capable of eliminating early cells, in which the virus is
reactivated [44], thereby containing viral rebound after treatment
interruption.
The BCN 01 trial evaluated for the first time the safety and immuno-
genicity of a heterologous prime/boost regimen of the ChAdV63.
HIVconsv and MVA.HIVconsv vaccines in a cohort of 24 individuals,
who were diagnosed with well-documented acute/recent HIV-1 infec-
tion and were treated immediately with cART including Tenofovir/
Emtricitabine/Raltegravir. In this population, we demonstrate a marked
shift in immunodominance profiles of HIV-1-specific T-cell responses
towards conserved T-cell epitopes, along with high in vitro viral inhibi-
tion capacity without signs of immune exhaustion. These findings may
prove critical for future successful combination ‘kick and kill’ eradica-
tion strategies [44–46].
2. Methods
2.1. Trial Design and Study Participants
Trial BCN 01was a phase I, open-label, non-randomized,multicenter
prime/boost therapeutic vaccination study in acute and recently HIV-1-
infected individuals to evaluate the safety and immunogenicity of a vac-
cination regimen of the ChAdV63.HIVconsv and MVA.HIVconsv vac-
cines using two intervals between the prime and boost. Study
participants were recruited at two HIV-1 units (Fundació Lluita contra
la Sida at Hospital Universitari Germans Trias i Pujol, Badalona and Hos-
pital Clínic, Barcelona). Individuals with confirmed acute/recent HIV-1
infection (b6 months from estimated HIV-1 acquisition), who fulfilled
all eligibility criteria, were enrolled and started on cART with an INSTI-
based regimen (Tenofovir/Emtricitabine plus Raltegravir). Complete
list of inclusion/exclusion criteria is available at NCT01712425. Patients
were sequentially allocated into the Long arm first (thefirst participants
1–12) followed by the Short (participants 13–24) arm later. These two
arms had a 24- or 8-week interval between the ChAdV63.HIVconsv
prime and MVA.HIVconsv boost administrations in the Long and Short
arm, respectively, and were chosen to assess whether or not the MVA.
HIVconsv boost given 24weeks after the ChAdV63.HIVconsv vaccine in-
stead of the previously reported 8-week interval [25] was able to induce
higher and/or longer-lasting HIVconsv-specific responses. The rational
for this is that ChAd vaccines may persist for longer period of time com-
pared to other (viral) vectored vaccines and could thus induce a more
robustmemory T cell responses. Sequential recruitmentwas performed
to reduce the total duration of the trial and ensure that participants
were suppressed for a similar period of time when entering into future
roll-over study BCN 02-Romi (NCT02616874) involving analytical cART
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viduals who commenced the same cART regimen andwere followed for
60 weeks, but did not receive any vaccine (Controls). This group was
only introduced to address potential differences in viral reservoir
decay between any of the two vaccination arms and the natural decay
of the 1st year of INSTI-based cART when started at acute/recent stages
of HIV-1 infection. No safety or immunological analyseswere conducted
in the control arm as HIV-1-specific T-cell responses were expected to
contract once cART mediated viral suppression was achieved. Flow
chart of the study design and patient disposition is depicted in Fig. 1a,
and the chronogram of the study is shown in Fig. 1b.
Criteria for documented acute and recent infection included plasma
HIV-1 RNAwith Ab (EIA) negativity, Gagp24 antigen assay positivity, an
indeterminate Western immunoblot signal or the absence of p31 band
in a positive Western blot. Days since estimated HIV-1 acquisition and
Fiebig staging at treatment initiation time point were defined according
to the time since known exposure, acute antiretroviral syndrome and/or
results of clinical laboratory tests at the time of HIV-1 diagnosis [47].
The study protocol as well as patient information sheet and consent
formswere discussed, reviewed and approved by the Community Advi-
sory Committee of the HIVACAT program. All patients provided written
informed consent before enrolment. The study was approved by the in-
stitutional ethical review board of both Hospital Universitari Germans
Trias i Pujol and Hospital Clinic (Reference Nr AC-11-027) and by the
Spanish Regulatory Authorities (EudraCT 2011-000846-39, IND ap-
provals with Nr 12-016 & 12-017). Risk of Genetically Modified Organ-
ism release to the environment was evaluated by the Ministry of
Environment (B/ES/12/10 & B/ES/12/09). ClinicalTrials.gov identifier:
NCT01712425
2.2. Procedures
Vaccinations started after 6 months on stable cART andwith plasma
virus load (pVL) b50 copies/mL (week 24 of trial = C0). The ChAdV63.
HIVconsv and MVA.HIVconsv vaccines were GMP manufactured at the
Clinical Biomanufacturing Facility, University of Oxford, UK and IDT
Biologika GmbH, Germany, respectively [19,24,48]. All vaccines were
stored below −65 °C until use. Vaccines were thawed no more than
30 min prior to injection. Vaccination with 5 × 10 [10] virus particles
(vp) of ChAdV63.HIVconsv at week 0 (C0) was followed by 2 × 10 [8]
plaque-forming units (PFU) of MVA.HIVconsv at weeks 24 or 8 (M0).
Vaccines were administered by intramuscular needle injection into
the deltoid region of both arms (each dose was divided between two
arms). The study entailed a total of 24 weeks of clinical and laboratory
follow-up after the last vaccination. Visits at 1, 4, 12 and 24 weeks
after MVA.HIVconsv boost are designated M1, M4, M12 and M24, respec-
tively. Antiretroviral treatment was maintained during the trial in all 48
individuals.
2.3. Outcomes
The primary objective of the study was to evaluate the safety of
ChAdV63.HIVconsv and MVA.HIVconsv vaccines administered sequen-
tially in a heterologous prime-boost regimen with two intervals to
HIV-1-positive adults. Local and systemic eventswere solicited prospec-
tively for a minimum of 7 days following each immunization. Both local
and systemic events were graded according to NIH Division of AIDS. Ad-
verse Events (AEs) were specified as unrelated, unlikely, probably or
definitely related to the vaccination.
Secondary endpoints included several immunological and virologi-
cal readouts. Total HIV-1 and HIVconsv-specific T cells were assessed
using cryopreserved peripheral blood mononuclear cells (PBMC) ob-
tained at week 0 as baseline (BL: at day of cART initiation); week 24
(C0: pVL b 50 copies/mL, before vaccination); weeks 1 and 4 after
ChAdV63.HIVconsv (C1 and C4); and at and 1, 4 and 24 weeks after
MVA.HIVconsv (M0, M1, M4 and M24) using an IFN-γ-detectingenzyme-linked immunoabsorbent spot (ELISpot) assay. The IFN-γ
Mabtech kit was used according tomanufacturer's instructions. All pep-
tides used in the study were 15-mer peptides overlapping by 11 amino
acid residues covering the full HIV-1 proteome consensus for subtype B
and were obtained through the NIH AIDS Reagent Program, except for
the HIVconsv immunogen sequence, for which a matching 199-
peptide set (Ana Spec, San José, CA; 95,131) was generously donated
by the International AIDS Vaccine Initiative. Peptides were combined
into 6 pools P1-P6 of 32–33 peptides per pool corresponding to the
HIVconsv vaccine insert (IN pools for ‘inside’ the immunogen) and 12
pools of 39–67 peptides per pool spanning the rest of the HIV-1 viral
protein sequences (OUT pools for outside the immunogen). All peptides
pools were tested in duplicates. The final concentration of individual
peptides in the ELISpot assay was 1.57 μg/mL. Medium only was used
as no-peptide negative control in quadruplicate wells, and PHA (1
μg/mL) and a CEF peptide pool (2 μg/mL) consisting of 23 previously de-
fined human CD8+ T-cell epitopes from cytomegalovirus, Epstein–Barr
virus and influenza virus (C.T.L. OH, USA) were added as positive con-
trols. All peptide stocks were stored at −80 °C until use. Spots were
counted using an automated Cellular Technology Limited (C.T.L., OH,
USA) ELISpot Reader Unit. The threshold for positive responses was de-
fined as at least 50 spot-forming units (SFU)/106 PBMC (5 spots per
well) and responses exceeding the mean number of SFU in negative
control wells plus 3 SD of the negative control wells, or 3x the mean
of negative control wells, whichever was higher.
For flow-cytometry and CD8+ T-cell suppression assays, cryopre-
served PBMCs were used from the vaccination time point (C0), at peak
of vaccine-induced T cells (M1 or M4) and at the end of trial visit
(M24). PBMC were CD8+ T-cell depleted by magnetic bead separation
(MACS Milteny Biotec) and stimulated with PHA (5 μg/mL) in RPMI
10% fetal bovine serum (R10). After 3 days of stimulation, the CD4-
enriched fraction was infected by spinoculation with HIV-1 BaL and
IIIB isolates at a multiplicity of infection (MOI) of 0.01. HIV-1-infected
cells were cultured in duplicates or triplicates in R10 medium with
20 IU/mL of interleukin 2 in 96-well round-bottomed plates, alone or to-
gether with unstimulated CD8+ T cells obtained by positive magnetic
bead separation from an additional vial of PBMC thawed on the same
day. Cultures at different CD8+ effector:CD4+ target ratios (E:T of 1:1,
1:2 and 1:10) were harvested after 6 days. Cells were stained first
with Aqua Live/Dead and fixedwith 1% paraformaldehyde/20 μg/mL ly-
solecithin at room temperature, permeabilized with cold 50%methanol
followed by 0.1% Nonidet P-40, and finally stained with anti-Gag p24
(KC-57-FITC; Beckman Coulter), anti-CD3 (APC-Cy7, BD Biosciences),
anti-CD4 (PerCP, BD Biosciences), and anti-CD8 (APC, BD Biosciences)
mAbs. CD8+ T-cell antiviral activity was expressed as percentage of in-
hibition calculated as: [(fraction of p24+ cells in CD4+ T cells cultured
alone) – (fraction of p24+ in CD4+ T cells cultured with CD8+ T
cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.
Data previously generated from cART-suppressed individuals treated
during chronic HIV-1 infection [49] and from a longitudinal observa-
tional cohort of elite and viremic controller individuals (EO-09-042)
were used for comparison of CD8+ T-cell antiviral activity from early
cART-treated BCN 01 participants. Elite and viremic controller individ-
uals were defined as individuals with sustained levels of pVL b50 or
b2000 copies/mL, respectively, for more than 10 years in the absence
of cART. Total CD8-depleted cells from day 0 and CD4-enriched fraction
from day 3 were stained for the exhaustion marker PD-1 using mAb
conjugated to PE (BioLegend).
To quantify the size of the peripheral blood proviral reservoir, lysed
extracts from 2.5 × 106 CD4+ T cells were used to measure total cell-
associated HIV-1 DNA by ddPCR with primers and probes binding
within 5′-LTR and Gag [50]. The RPP30 cellular gene was quantified in
parallel to normalize sample input [39,50,51].
To evaluate HIV-1 RNA below 40 copies/mL, 4–8 mL of plasma sam-
pleswere ultracentrifugated at 170,000g at 4 °C for 30min before quan-
tification using the Abbott Real-Time HIV-1 assay (Abbott Molecular
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Fig. 1.Disposition of participants and flow chart of the study. Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial. Trial BCN 01was a non-randomized, open label, sequence allocation study. CONSORT diagram delineates
the study enrollment of 54 subjects who underwent sequential allocation to the long, short vaccination arms and the control group. Three subjects withdrew from the study before vaccination and/or week 24 and were replaced during enrollment
period. All the participants in the Long and Short arms (b) received the ChAdV63.HIVconsv andMVA.HIVconsv vaccines, while 24 individuals in the control arm did not receive any vaccine. All 48 subjects completed the study as per protocol. The 24









69B. Mothe et al. / EClinicalMedicine 11 (2019) 65–80Inc.). Serial dilutions of a positive control down to 5 HIV-1 RNA
copies/mL were used as a standard curve to calculate quantitative
values from raw qPCR 51CT data [39].
2.4. Statistical Analysis
Trial BCN 01was an exploratory pilot study and, because of the small
sample size of the study, was not powered to detect significant differ-
ences between arms and only allowed to detect trends in safety, immu-
nological and virological effects, which collectively inform the design of
future studies. The safety endpoints were described in the Long and
Short arms and summarized by the number and percentage of AEs
and their grading. Immunogenicity endpoints were described in the
Long and Short arms. The minimum breadth of the T-cell response
was estimated as the number of peptide pools eliciting a positive re-
sponse. The total frequency of HIV-1-specific IFN-γ+ T cells was calcu-
lated as the sum of the SFU/106 PBMC stimulated with individual
peptide pools.
Differences in the breadth and frequency of the HIV-1-specific re-
sponses and virologic determinations between two longitudinal deter-
minations in the same individual were assessed using a Wilcoxon
signed-rank test. Differences between groups were compared using a
Mann–Whitney U-test or Kruskal-Wallis, ANOVA tests as indicated.
Only the reservoir measurement (proviral DNA) was performed in the
Control arm. Correlations between the HIV-1-specific responses, provi-
ral DNA and clinical parameters were performed using non-parametric
Spearman's rank correlation. Missing data due to technical problems
were censored from the analysis, and no imputation techniques were
used. Censoredmatched pairs of ultrasensitive viral loadwere analyzed
using the paired Prentice-Wilcoxon test. Statistical significance was set
at 5% for all the univariate tests. The analyses were performed with R
(v3.0.2) and GraphPad Prism (v5.01) for Mac OS X (San Diego, CA).
Flow data were analyzed using FlowJo software.
3. Results
3.1. Participants Enrolled in the Study
Between October 5, 2012 and April 15, 2013, 27 acute/early HIV-1-
infected individuals were sequentially enrolled into the Long and
Short arms of BCN 01. Three participants withdrew consent before vac-
cinations due to suboptimal compliance expectations for follow-up
visits or reasons unrelated to the trial. Between May 27, 2013 and
April 10, 2014 individuals were enrolled into the no-vaccine arm
(Fig. 1b). Recruitment into the BCN 01 trial was enhanced by an intensi-
fied MSM testing campaign, which resulted in a gradually earlier-Table 1




Median age at HIV-1 diagnose 41 (30–54)
Sex (M/F) 11/1
MSM/HTSa 9/3
Days since HIV-1 to cART, median (range) 91 (28–203)
Fiebig stage at cART initiation,
(numer and Percent of individuals)
V (6, 50%)
VI (6, 50%)
Log10 of pVL before cART, median (range) 5.04 (3.20–5.84)
CD4 (cells/mm3) before cART, median (range) 574 (299–785)
CD4 (cells/mm3) at week 60, median (range) 664 (291–986)
CD4/CD8 ratio before cART, median (range) 0.54 (0.17–1.26)
CD4/CD8 ratio at week 60, median (range) 1.10 (0.68–1.66)
Number of individuals with B*27/B*57/B*58 3 (3/0/0)
a MSM (men who have sex with men)/HTS (heterosexual).diagnosed and younger population over the recruitment periods. All
the 48 participants showed over 99% visit adherence and all completed
the study. Study participants' demographics are given in Table 1. Plasma
viral loads b50 copies/mL were reached within median of 12 weeks in
all groups as expected for an integrase inhibitor-based regimen
(INSTI) (Fig. 2a). Baseline CD4+ T-cell counts (Fig. 2b) and CD4+/
CD8+ T-cell ratio (Fig. 2c) significantly increased during the trial during
thefirst year of cART. Therewas a tendency in older individuals towards
lower CD4+ T-cell counts at baseline (Spearman r =−0.27; p = 0.06)
and poorer CD4+ T-cell recovery over the first 60weeks after treatment
initiation (Spearman r = −0.24; p = 0.09) (Appendix Fig. 1).
3.2. Both ChAdV63.HIVconsv and MVA.HIVconsv vaccines were safe and
well tolerated
All 24 subjects from the Long and Short arms were included in the
safety analysis. Overall, the vaccines were well tolerated. One partici-
pant experienced a severe adverse event (SAE) prior to the administra-
tion of the ChAdV63.HIVconsv vaccine (acute pancreatitis requiring
hospitalization). No other serious adverse reactions or suspected unex-
pected adverse reactions occurred during the study. A total of 334 AE
were recorded during the study (182 in the Long Arm and 152 in the
Short Arm, Chi-square, p = 0.25), the majority of which (300, 90%)
were mild or moderate (Grade 1–2). The number of AEs per patient
was not significantly different between the Long and Short vaccination
Arm (Chi-square, p = 0.590).
The summary of local and systemic AEs related to vaccination is
shown in Table 2. Local and systemic events after vaccination occurred
in 22/24 individuals. Peak of reactogenicity was observed at 24–48 h
after vaccination and resolved spontaneously within 3 days. The most
frequently reported local reactogenicity AEwas a Grade-1 pain reported
in both the Long and Short arms, andmore frequently reported after the
MVA.HIVconsv vaccination than after the ChAdV63.HIVconsv. Themost
frequently reported systemic reactogenicity event was malaise. As for
laboratory abnormalities, no Grade 3 or 4 abnormalities were observed
in the performed hematological and biochemical tests (data not
shown). Overall, the vaccines were safe and consistent with safety and
tolerability data previously observed in HIV-1-negative volunteers [22,
25].
3.3. ChAdV63.HIVconsv-MVA.HIVconsv regimen induced high frequencies
of T cells against conserved regions of HIV-1 in all vaccine recipients
Peptide pools P1-P6 covering the HIVconsv immunogen (778 amino
acids) contained 15-mer peptides overlapping by 11 amino acids






38 (27–48) 34 (19–62)
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4.80 (3.35–5.48) 5.18 (2.91–6.39)
519 (309–990) 482 (224–1014)
684 (437–1161) 785 (451–1876)
0.60 (0.27–2.15) 0.68 (0.14–2.38)
1.29 (0.73–2.34) 1.12 (0.53–2.34)
0 (0,0,0) 3 (1/3/0)
Fig. 2. Immune recovery after early treatment initiation. Evolution of pVL (a) and CD4 T-
cell counts (b) and CD4/CD8 ratio (c) over the first 60 weeks after early-cART start with
TDF/FTC/RAL in study participants.
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censored due to low positive controls and/or high background. T-cells
to the HIVconsv immunogen of median (range) frequency of 286 (55-
2,640) SFU/106 PBMC were detected in 50% of study participants in
the Long (Fig. 3b) and Short (Fig. 3c) arms equally at HIV-1 diagnosis
and before cART (BL). Individuals with and without HIVconsv pre-
existing responses did not differ in duration with untreated infection
or pre-cART viremia. All HIV-1-specific T cells were significantly re-
duced after initiation of cART and viral suppression to frequencies of
median of 75 (0–476) SFU/106 PBMC (BL vs C0; Wilcoxon signed-rank,
p = 0.0173). All vaccine recipients completed ChAdV63.HIVconsv-
MVA.HIVconsv immunizations and all 24 (100%) showed an absolute
increase in HIVconsv-specific IFN-γ-producing T cells during the
study; in 15 individuals (63%) showed increase already afterChAdV63.HIVconsv and the remaining 9 individuals (37%) after MVA.
HIVconsv. There was no difference between the Long and Short arms,
whereby 8 and 7 subjects responded to ChAdV63.HIVconsv, and 4 and
5 responded only after MVA.HIVconsv, respectively. For all individuals,
the peak of total T-cell frequencies (sum of frequencies to HIVconsv
P1-P6 pools) was detected after MVA.HIVconsv. Individuals in the
Long arm showed a tendency towards reaching peak responses more
slowly than subjects in the Short Arm with 2 vs 6 individuals peaking
at 1 week (M1) and 9 vs 6 individuals peaking at 4 weeks after MVA.
HIVconsv (M4), respectively (Chi-square, p= 0.08). Altogether, median
(range) total peak total frequencies of HIVconsv-specific T cells reached
938 (73-6,805) SFU/106 PBMC, which represented an absolute increase
in the frequencies of 750 (124-1,948) and 1,015 (73-6,535) SFU/106
PBMC from the time point before vaccination (C0) in the Long and
Short arm, respectively (Wilcoxon signed-rank, p b 0.0001) (Fig. 3d).
The longevity of vaccine-elicited responses was not statistically differ-
ent between the Long and Short Arms as frequencies of total
HIVconsv-specific T cells were 390 (60-1,701) and 140 (0-1,567) SFU/
106 PBMC at 24 weeks after the MVA.HIVconsv administration in
these arms (M24), respectively (Fig. 3e).
3.4. ChAdV63.HIVconsv-MVA.HIVconsv vaccination elicited responses to
multiple epitopes within the HIVconsv immunogen
Effector CD8+ T-cell recognition of multiple conserved epitopes will
likely be one of the key features of a successful HIV-1 vaccine. Vaccine
recipients responded to median (range) of 4 [1–6] peptide pools out
of 6 vaccine peptide pools P1-P6 (Appendix Fig. 2). There was no signif-
icant difference in the specific T-cell frequencies for the different pools
(ANOVA test, p = 0.3211, Fig. 4a), indicating balanced and polyspecific
vaccine-induced responses across the HIVconsv immunogen. Most
(83%) of the HIVconsv peptide pool-specific T cells detected at peak im-
munogenicity were considered de novo responses as they were not de-
tectable before cART initiation (BL), when high levels of plasma viremia
were present. This was the case for peptide pools P4-P6 (Fig. 4b), which
covered the conserved regions of polymerase, integrase, Vif, and Env
gp41 and gp120 regions included in the HIVconsv immunogen. The
highest proportion of pre-vaccination responses was directed against
pool P1 covering partial Gag sequences (Fig. 4b). Finally, in individuals
who showed response to HIVconsv peptide pools at the time of HIV-1
diagnosis (12 individuals, 16 responses in total), vaccination effectively
boosted their pre-existing responses. Indeed, these presumably ex-
panded T cells reached higher frequencies of median (range) of 497
(87–3250) SFU/106 PBMC than de novo vaccine-induced T cells of me-
dian (range) of 156 (0–1440) SFU/106 PBMC (Mann–Whitney U-test,
p = 0.0029) (Fig. 4c).
3.5. ChAdV63.HIVconsv-MVA.HIVconsv vaccination shifts immuno-
dominance T-cell patterns towards conserved regions of the HIV-1 prote-
ome without induction of responses against junctional regions
Next, we assessedwhether or not the HIVconsv vaccinations led to a
non-specific expansion of T cells targeting HIV-1 regions not present in
the HIV-1 immunogen or T cells specific for unrelated co-pathogens.
The non-HIVconsv HIV-1-specific responses referred to as the OUT pep-
tide pools and those directed to the CEF peptide pool were determined
in an IFN-γ ELISPOT assay. The dominance of HIVconsv-specific re-
sponses was calculated at each time point as the percentage of
HIVconsv-specific T-cell frequencies divided by the total HIV-1
proteome-specific (HIVconsv + OUT) T-cell frequencies. A significant
reduction in total HIV-1-specific T cells after viral suppression by cART
and elimination of HIV-1 antigenemia was observed (Wilcoxon
signed-rank, p b 0.001 at C0 (Fig. 5a). No expansion of T cells targeting
HIV-1 regions outside of the immunogen was noted over the vaccina-
tion time points, indicating that the vaccines selectively expanded
HIVconsv-specific T cells. An effective shift of response patterns towards
Table 2
Number and proportion of volunteers suffering local or systemic side effects related to vaccination.
ChAdV63.HIVconsv MVA.HIVconsv
Grade 1 Grade 2 Grade 3 Any Grade 1 Grade 2 Grade 3 Any
Local reactogenicity
Redness/Erythema (≥2.5 cm diameter)a
Left arm 0 0 0 0 (0%) 1 0 0 1 (4%)
Right arm 0 0 0 0 (0%) 1 1 0 2 (8%)
Induration (≥2.5 cm diameter)b
Left arm 0 0 0 0 (0%) 0 0 0 0 (0%)
Right arm 0 0 0 0 (0%) 0 0 0 0 (0%)
Local pain
Left arm 13 1 1 15 (62%) 13 9 1 23 (96%)
Right arm 12 1 0 13 (54%) 11 9 0 20 (83%)
Systemic adverse events
Fever 0 0 0 0 (0%) 2 0 1 3 (12%)
Headache 8 2 1 11 (46%) 7 5 1 13 (54%)
Malaise 5 5 1 11 (46%) 8 8 2 18 (75%)
Nausea 0 0 0 0 (0%) 0 0 0 0 (0%)
Diarrhea 1 1 0 2 (8%) 3 0 1 4 (17%)
Sweating 2 2 0 4 (17%) 7 0 0 7 (29%)
Myalgia 2 5 0 7 (29%) 8 5 2 15 (62%)
Anorexia 2 0 0 2 (8%) 1 2 0 3 (12%)
Abdom pain 0 1 0 1 (4%) 3 3 0 6 (25%)
Note to local AE:
a Injection-site erythema not reaching Grade 1 DAIDS criteria (b 2.5 cm in diameter) was observed in 4 (17%) and 4 (17%) participants in the left/right arm, respectively after the
ChAdV63.HIVconsv vaccination, and in 12 (50%) and 9 (37%) participants on the left/right arms, respectively after the MVA.HIVconsv vaccination.
b Injection-site induration not reaching Grade 1 DAIDS criteria (b 2.5 cm in diameter) was observed in 2 (8%) and 3 (12%) participants in the left/right arm, respectively after the
ChAdV63.HIVconsv vaccination, and in 17 (71%) and 14 (58%) participants on the left/right arm, respectively after the MVA.HIVconsv vaccination.
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cination with median (range) of 58% (7%–100%) of the total anti-HIV-1
immune responses. Despite some decay of vaccine-elicited T-cell fre-
quencies, this focus was maintained over time and was still 33% (0%–
100%) of all detectable HIV-1 responses 24 weeks after the last vaccina-
tion (M24) (Fig. 5b). Similarly, no increases in the frequency of re-
sponses to the CEF peptides were observed over the vaccination time
points (Fig. 5c).
Additionally, we determined the immunogenicity of potential junc-
tional neo-epitopes located across the adjacent segment junctions of
the HIVconsv immunogen [19] by comparing response rates to two
sets of peptide pools with and without junctional peptides. In contrast
to what was observed in an HIV-1-negative cohort where ~20% of in-
duced responses were specific for junctions [24], responses to both
sets of peptide pools were of comparable frequency all individuals
(Fig. 5d), indicating that responses against junctional regionsweremin-
imal if induced at all.3.6. Early cART preserves antiviral function of CD8+ T cells and might
contribute to an efficacious vaccine response
To determine CD8+ T-cell mediated viral inhibitory capacity against
HIV-1 BaL and IIIB isolates at different CD8:CD4 ratios (E:T = 1:1, 1:2
and 1:10), longitudinal cryopreserved-and-thawed samples obtained
at 6 months on stable cART and just before vaccination (C0), at the
peak of vaccine-induced immunogenicity (M1 or M4, collectively
Mpeak) and at the end of trial in all individuals from the Long and
Short arms (M24) were used in in vitro viral replication inhibition as-
says. Data previously generated from individuals virologically sup-
pressed, who were treated during chronic HIV-1 infection [49] and
from eight long-term controller individuals were used for comparison
with the CD8+ T-cell antiviral activity from early-cART-treated BCN 01
participants. CD8+ T-cell viral inhibition of the BaL virus was higher in
vaccinated individuals at C0 atmedian (range) of 68% (37–87%) viral in-
hibition when compared to the same day levels described in individuals
treated during chronic HIV-1 infection (median 20%,Mann–Whitney U-test, p b 0.0001) and closer to levels observed in cohorts of elite and vi-
remic controllers (median 84%, Mann–Whitney U-test, p = 0.0074,
Fig. 6a). This high suppressive capacity was maintained during the en-
tire vaccination period, was also observed at lower E:T ratios and was
confirmedwith both 2 clade B viruses tested (Fig. 6b). In linewith an ef-
fective antiviral T-cell response, the levels of the PD-1 exhaustion
markers on total CD8+ T cells weremaintained at low levels throughout
the study period with median (range) of 23% (10–45%) of CD8+ T cells
suggesting that early cART initiation might preserve CD8+ T-cell func-
tion and consequently allow for an effective vaccine response (Fig. 6c).3.7. Early cART, but not HIVconsv vaccination limits the size of latent viral
reservoir
To determine whether vaccine-induced immune activation resulted
in an increased HIV-1 replication despite cART, pVL was measured just
prior to and at 1 week after the MVA.HIVconsv administration (M0
and M1) in all vaccinated subjects using both standard and ultrasensi-
tive assays. Overall, 6 participants had plasma HIV-1 RNA “blips” of me-
dian (range) of 200 (37-119) RNA copies/mL, whereby 40 copies/mL is
the detection limit, while on reported optimal cART adherence along
the entire trial follow-up period (data not shown). Using the ultrasensi-
tive pVL assay, plasma viremia was detectable in 92% of individuals at
M0 or M1 (Fig. 7a). We observed 8 patients with a 2-fold increase in ul-
trasensitive pVL 1week after vaccination (M1), but changes in the ultra-
sensitive pVL in the overall cohort were not statistically significant
between the two tested time points (Fig. 7a). In addition, there was
no correlation between the frequencies of HIVconsv-specific IFN-γ-
producing cells at peak and the detected increases in plasma viremia
(Spearman r 0.3122, p = 0.1375; Fig. 7b).
To determine the proportion of total circulating CD4+ T cells harbor-
ing proviral DNA and to identify potential changes in the viral reservoir
size induced by vaccination, total HIV-1 DNA copies in purified PBMC-
derived CD4+ T cells were quantified longitudinally. Total HIV-1 DNA
was measured just prior to vaccination when all subjects had achieved
pVL b50 copies/mL after 24 weeks under stable cART and at 12 and
Fig. 3. Vaccination immunogenicity. Cryopreserved, unexpanded PBMC were stimulated with pools P1–P6 of overlapping 15-mer peptides across the HIVconsv immunogen in an IFN-γ
ELISPOT assay. (a) Schematic representation of the employed conserved regions in theHIV proteome from different HIV-1 clades included in theHIVconsv immunogen and distribution of
the set of 6 peptide pools used for immunogenicity studies. Magnitude of total HIVconsv-specific responses (sum of SFU/106 PBMC to pools P1-P6) over trial duration in the Long (b) and
Short (c) vaccination arms are shown. (d) Totalmagnitude of HIVconsv-specific responses before and at peak immunogenicity in all vaccinated individuals. Median total frequency for the
entire cohort is shown in red. Wilcoxon signed-rank p value is shown (e) Comparison of total magnitude of HIVconsv-specific responses between Long and Short vaccination arms at
different time points of the clinical study. Mann–Whitney U-test is used for comparisons between Long and Short arms, and Wilcoxon signed-rank for comparisons within timepoints
in the same individual.
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after treatment initiation). Proviral DNA from 24 early treated, but not
vaccinated individuals (Control) was measured for comparison with
the natural decay due to cART initiation. At pre-vaccination, total HIV-
1 DNA was not statistically different between the Long, Short and Con-
trol arms with median (range) of 815 (134-5,660), 639 (24-3,289)
and 358 (54-7,665) copies of total HIV-1 DNA/106 CD4+ cells, respec-
tively (Fig. 7c). Peripheral blood CD4+ T-cell proviral reservoir showed
similar decay kinetics in all groups. Overall, in the compiled BCN 01 co-
hort (n=48),we observedmedian (range) of 342 (5.4-4,565) copies of
HIV-1 DNA/106 CD4+ cells at 1 year after treatment initiation. These
levels of proviral DNA were 3-fold lower than values in virallysuppressed individualswho started cARTduring chronicHIV-1 infection
(median of 1065 copies/106 CD4+ T cells) [49]. The proviral DNA decay
was consistent with a decay over the first year of early initiated cART
[50], but was not further accelerated by the ChAdV63.HIVconsv-MVA.
HIVconsv vaccinations (Fig. 7d).
Levels of proviral DNA in PBMC-derived CD4+ T cells measured at
pre-vaccination (BL) and at the end of study (M24) did not correlate
with estimated days since HIV-1 acquisition to cART initiation and
were not associated with either the HIVconsv-specific nor the total
HIV-1-specific T-cell frequencies (data not shown). Overall, the fre-
quency of CD4+ T cells harboring HIV-1 DNA correlated well with pre-
cART viremia in acute/recent infection (Spearman r = 0.54, p b
Fig. 4. Breadth of vaccine-elicited HIVconsv-specific T-cells. (a) Comparison (ANOVA p-value) of the frequency of each participant's response to individual peptide pools at the peak
immunogenicity time point after MVA.HIVconsv booster vaccination and (b) percentages of participants showing a detectable response (‘responders’) to HIVconsv peptide pools either
before any vaccination (white bars) or at the peak immunogenicity time point (gray bars). (c) Comparison of the frequency of responses detected at the peak immunogenicity time
point reflecting either de-novo induced or vaccine-boosted (‘pre-existing’) responses. Mann–Whitney U-test p value is shown.
73B. Mothe et al. / EClinicalMedicine 11 (2019) 65–800.0001 at C0, and Spearman r = 0.59, p b 0.0001, at M24; see Appendix
Fig. 3).
4. Discussion
The present BCN 01 trial data show that a heterologous regimen
using the ChAdV63.HIVconsv and MVA.HIVconsv vaccines in a cohort
of early-treated individuals with acute or recent HIV-1 infection was a
safe and effective strategy to shift the immunodominance of the total
HIV-1-specific T-cell response towards conserved regions of HIV-1. Vac-
cination led to a marked and highly selective expansion of pre-existing
as well as induction of new T-cell responses to HIVconsv, but failed to
impact the size of the in vivo latent viral reservoir.
A successful therapeutic vaccination may ultimately be achieved by
an optimal T-cell immunogen and the use of highly immunogenic vac-
cine vector or vector combination, which can refocus HIV-1-specific
CTL response to vulnerable sites of the virus [15,19–21,52]. Here, we
tested the immunogenicity of two heterologous prime-boost regimens
with simian adenovirus and MVA-vectored vaccines expressing the
first-generation conserved immunogen HIVconsv in a population of
early-diagnosed and early-treated HIV-1-positive individuals in Barce-
lona, Catalonia, Spain. Overall, the vaccines were well tolerated withside effects limited to Grade 1 and 2, whereby most AEs judged to
be related to the vaccination were transient and resolved spontane-
ously within 3 days. These data support the previously reported
safety profile of the combined ChAdV63.HIVconsv and MVA.
HIVconsv vaccination in HIV-1-negative individuals immunized
with the same regimen [25].
Our analyses show that T-cell responses to conserved regions ofHIV-
1 were sub-dominant in natural HIV-1 infection [53,54]. Administration
of HIVconsv vaccines was able to induce broad and potentially novel T-
cell responses by strongly refocusing the HIV-1-specific T cells to con-
served epitopes contained in the immunogen insert. These responses
were of high frequency, although lower than vaccine responses seen
in the HIV-1-negative individuals included in the earlier HIV-CORE 02
trial [24]. In the HIV-CORE 02 trial, median (range) frequency of
HIVconsv-induced peak responses induced in the ChAdV63.HIVconsv-
MVA.HIVconsv arm was 5150 (1475–16,510) SFC/106 PBMC24. How-
ever, it is important to note that HIV-CORE 02 used freshly isolated
PBMC IFN-γ ELISPOT assays, which has been shown by reference labs
and some of the co-authors using HIV-CORE 02 samples to lead to ap-
proximately 5-times higher frequency when compared to frozen-and-
thawed cells (Spearman r = 0.9156; P b 0.0001). Therefore, peak
vaccine-induced T-cell levels observed in BCN 01 were comparable to
Fig. 5. Changes in T-cell dominance patterns. (a) Schematic representation of the average distribution of total HIV-1 T-cells among different HIV-1 proteins at baseline (BL), its decrease
during viral suppression and its expansion at peak responses. HIVconsv-specific responses are shown in purple. Sizes of pie charts are to scale with total frequencies of responses. Acc -
Accessory proteins. (b) Median frequency of total HIVconsv-specific T cells (green bars) and changes in median HIVconsv immunodominance (red line) are shown over time. (c) Mean
± SD frequencies of T cells specific for OUT and CEF peptide pools are shown over time. (d) Comparison of the frequency of individual HIVconsv peptide pool responses detected in 15
study subjects using two sets of 15-mer peptides covering (P1-P6, + junctions) or avoiding (P1-P6,− junctions) the junctional regions is shown. Wilcoxon signed-rank t-test is used.
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siderably stronger than responses reported in past therapeutic vaccine
trials such as the ones using canarypox ALVAC-HIV vaccine [6] or ho-
mologous vaccinationswithMVA-B [55] in chronically suppressed indi-
viduals. Thus, our data strongly suggest that potent heterologous prime-
boost vaccination regimens including an adenovirus-vectored prime as
well as early cART initiation contribute critically to the effective refocus
and boost of T-cell responses to relevant epitopes in BCN 01. Althoughlimited by the non-randomized nature of the study and the small
size of the clinical trial, we did not observe statistically separable dif-
ferences in the frequency or breadth of induced responses, function-
ality or longevity between the longer and the shorter vaccination
intervals. This does not exclude the possibility that larger, random-
ized trials may reveal some differences between different dosing in-
tervals though, and that these differences could have a potential
effect on viral control.
Fig. 6. High CD8+ T-cell viral inhibitory capacity and low levels of PD-1-expressing CD8+ T cells in early-treated individuals. (a) Comparison (Mann–Whitney U-test) of levels of CD8+ T-
cell viral inhibition is shown for HIV-1Bal (E:T 1:1) in individuals, who started cART during chronic infection (Chronic), participants in BCN 01 (Early_cART) 24 weeks after cART initiation
and before any vaccination (C0), and elite and viremic controllers (EC/VC). (b) Levels of CD8+T-cell viral inhibition are shown forHIV-1Bal (E:T ratio 1:1, 1:2 and 1:10) for individuals in the
Long and Short Arms before vaccination (C0), at peak of vaccine-induced immunogenicity (Mpeak) and at the end of trial (M24). (c) Expression of PD-1 by CD8+ T cells for the same time
points.
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HIV-1 infection has recently been related to viral setpoint [4], suggest-
ing that early treatment initiation could help maintain necessary HIV-
1-specific CD8+ T-cell responses associated with subsequent control
of viremia. In line with this hypothesis, we observed also in our cohort
a more marked immune restoration (normal CD4/CD8 T-cell ratios)
[56], a reduced expression of immune exhaustionmarkers and stronger
CD8+ T-cell viral inhibitory capacity than those reported for individuals
who started treatment in the chronic phase of HIV-1 infection [49].
Some or all these factors might have contributed to an increasedimmune responsiveness to the therapeutic vaccination strategy tested
in this population.
Aside from the non-randomized nature of the trial, one potential ca-
veat of the present study was that the relative contribution of HIVconsv
vaccine-induced T cells to the total in vitro CD8+ T-cell inhibition activ-
ity could not be accurately estimated. Thus, although we document a
strong refocus of the specificity of the T-cell response after vaccination,
it remains unclear howmuch these responses added to the observed in-
hibition of viral replication in vitro. The increase in viral inhibition ca-
pacity could be limited due to the continuous presence of CD8+ T cells
Fig. 7. Changes in ultrasensitive pVL after MVA.HIVconsv booster vaccination and proviral DNA decay dynamics. (a) Copies of HIV-1 RNA per mL of plasma are shown for each vaccine
group just before MVA.HIVconsv (M0) and 1 week later (M1) with censored values below the limit of detection shown in gray. Prentice-Wilcoxon p values are shown. (b) Correlation
(Spearman r) between total frequency of HIVconsv-specific T cells at the peak immunogenicity timepoint and the absolute increase in pVL. (c) Total HIV-1 DNA copies/106 CD4+ T
cells for each vaccination group are shown at week 24 (before vaccination) and at week 56/60 after treatment initiation (Wilcoxon signed-rank p values are shown for comparisons
within timepoints in same individual) (d) Comparison (ANOVA) of fold change of proviral DNA over 1 year after viral suppression from week 24 of cART in all groups (mean ± SE).
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viral epitopes not covered by HIVconsv immunogen and/or insufficient
T-cell help stimulation, which improved vaccine immunogen designs
may overcome [15,19,21,57]. On the other hand, it is likely that the vac-
cination contributed to the prolongedmaintenance of responses able to
suppress HIV-1 replication in vitro, which would have been gradually
lost if no vaccine were administered. While in trial BCN 01, the non-
vaccinated control arm could not be tested for antiviral activity, this sce-
nario concurswith recently reported data from the London-based RIVER
trial (NCT02336074 [58]). In that trial, using the same vaccine combina-
tion along with vorinostat, the vaccinees maintained in vitro inhibitory
activity over time whereas placebo controls showed indeed a progres-
sive decay, suggesting that also in BCN 01, the vaccine was responsible
for the continuously high levels of antiviral activity observed.
Despite a strong expansion of T-cell responses to HIV-1, a prolonged
maintenance of antiviral activity of these responses with vaccination
and relatively low reservoir levels at the end of the trial [38,59], we
did not observe a more pronounced reduction in the size of the HIV-1
reservoir associated with vaccination when compared to non-
vaccinated individuals. Moreover, no differences in the viral reservoir
decay dynamics between the longer and the shorter vaccination regi-
men were noted. This does not exclude however the possibility that
more sensitive assays or larger, randomized trials and specially with
longer follow-up could reveal differences between vaccinated andnon-vaccinated individuals. However, the same was reported in other
therapeutic vaccine trials, where less immunogenic regimens were
tested in chronic cART-suppressed subjects [49,55]. In that sense, the re-
sults may not be surprising as no latency reversing agent was adminis-
tered in BCN-01 and vaccination did not induce robust signals of virus
reactivation either. In addition, the effect of vaccine-induced T-cells on
residual replicating cells in the tissue is unknown. Whether or not if ef-
fective, such elimination of HIV-1-producing cells in tissues would be
detectable by reservoir analyses in the peripheral blood remains to be
assessed.
Importantly, a change in T-cell immunodominance towards targets
of interest would not occur if the vaccination regimen led to a broad,
non-specific expansion of all HIV-1-specific T cells that existed before
vaccination. We assessed this by measuring longitudinally T-cell re-
sponses to regions of HIV-1 that both were and were not covered by
the HIVconsv immunogen, by documenting T cells to epitopes from un-
related viruses such as CMV, EBV and influenza virus aswell as by deter-
mining potential responses to junctional regions of the HIVconsv
chimeric protein. These analyses showed no signs of expansion of pre-
existing T-cell responses to HIV-1 regions not covered by the immuno-
gen or of responses to other viral infections. Interestingly, a marked ab-
sence of responses to junctional regions contained in the HIVconsv
sequence was also noted, which is in contrast to findings with the
same vaccination regimen in HIV-1-uninfected subjects [24] and
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HIV-1-negative versus already HIV-1-positive individuals. Alternatively,
another possible explanation could be that low-levels of HIVconsv
immunogen-specific T-cell responses already existed at pre-
vaccination time points in the already HIV-1-infected subjects and
that vaccination expanded these responses rather than induced them
de novo. Detailed T-cell receptor analyses on total T cells and epitope-
specific populations will be needed to address this question. Neverthe-
less, regardless of whether vaccination induced de novo responses or
expanded T cells from very subdominant populations, the results in
BCN 01 document for the first time an impressive plasticity in the
HIV-1-specific T-cell response patterns upon potent vaccination in
early-treated individuals. Thus, and to the best of our knowledge, this
is the first therapeutic HIV-1 vaccine trial able to demonstrate a shift
in the immunodominance of the virus-specific T cells towards con-
served regions of HIV-1 in a cohort of early-treated individuals. The
data provide strong rationale for the further development of this vac-
cine strategy and incorporation of this regimen into future kick-and-
kill approaches to address whether or not these responses can control
rebounding virus after cART interruption.
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